Pharmaceutical Wholesaler throughout New Zealand. Branches in Auckland, Whangarei, Hamilton, Palmerston North, Wellington, Nelson, Christchurch and Dunedin. We are part of the large health company Ebos which is owned by New Zealanders. Their head office is in Christchurch. Other companies in this group are HCL,( Healthcare Logistics) and One Link. These are both Auckland based companies and service both pharamcy and hospitals throughout NZ.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. | August 18, 2021

news image

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More

BUSINESS INSIGHTS

C-PATH AND REPLICA ANALYTICS COLLABORATION AIMS TO ACCELERATE RARE DISEASE RESEARCH

Replica Analytics | June 30, 2022

news image

Critical Path Institute and Replica Analytics, an Aetion company, announced a new partnership that involves leveraging synthetic data to further catalyze the generation of actionable solutions to accelerate drug development for rare diseases. Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility. Together...

Read More

PHARMACY MARKET

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

news image

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More

U.S. FDA ALLOWS PRIORITY REVIEW TO NEW DRUG APPLICATION FOR VERICIGUAT TREATING CHRONIC HEART FAILURE

Merck | July 17, 2020

news image

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with ...

Read More
news image

BUSINESS INSIGHTS

HARROW HEALTH ACQUIRES OPHTHALMIC SURGICAL DRUG CANDIDATE FROM WAKAMOTO PHARMACEUTICAL CO., LTD.

Harrow Health, Inc. | August 18, 2021

Harrow Health, Inc. an ophthalmic‑focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ-100, a preservative-free triamcinolone acetonide ophthalmic injection. MAQ-100 is marketed and sold by Wakamoto in Japan as MaQaid®. Following Japan’s Ministry of Health Labor and Welfare (or MHLW) approval, MaQaid was launched in Japan in 2010, ...

Read More
news image

BUSINESS INSIGHTS

C-PATH AND REPLICA ANALYTICS COLLABORATION AIMS TO ACCELERATE RARE DISEASE RESEARCH

Replica Analytics | June 30, 2022

Critical Path Institute and Replica Analytics, an Aetion company, announced a new partnership that involves leveraging synthetic data to further catalyze the generation of actionable solutions to accelerate drug development for rare diseases. Replica Analytics will help generate synthetic datasets across rare and orphan indications in which patient-level datasets are often quite small, which heightens considerations regarding data privacy and accessibility. Together...

Read More
news image

PHARMACY MARKET

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More
news image

U.S. FDA ALLOWS PRIORITY REVIEW TO NEW DRUG APPLICATION FOR VERICIGUAT TREATING CHRONIC HEART FAILURE

Merck | July 17, 2020

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for vericiguat, an orally administered soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in combination with ...

Read More